Balchem Co. (NASDAQ:BCPC - Free Report) - Analysts at Sidoti Csr dropped their Q1 2024 earnings per share (EPS) estimates for shares of Balchem in a research note issued to investors on Wednesday, April 24th. Sidoti Csr analyst K. May now expects that the basic materials company will earn $0.98 per share for the quarter, down from their previous forecast of $1.00. The consensus estimate for Balchem's current full-year earnings is $4.14 per share. Sidoti Csr also issued estimates for Balchem's Q2 2024 earnings at $1.00 EPS, Q3 2024 earnings at $1.06 EPS, Q4 2024 earnings at $1.06 EPS, FY2024 earnings at $4.10 EPS, Q1 2025 earnings at $1.09 EPS, Q2 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.19 EPS, Q4 2025 earnings at $1.18 EPS and FY2025 earnings at $4.59 EPS.
Balchem (NASDAQ:BCPC - Get Free Report) last posted its earnings results on Friday, February 16th. The basic materials company reported $0.95 EPS for the quarter, beating analysts' consensus estimates of $0.93 by $0.02. The firm had revenue of $228.70 million during the quarter, compared to the consensus estimate of $234.66 million. Balchem had a return on equity of 10.69% and a net margin of 11.77%. The company's quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.66 EPS.
Separately, StockNews.com downgraded Balchem from a "buy" rating to a "hold" rating in a research report on Thursday.
Read Our Latest Research Report on Balchem
Balchem Price Performance
Shares of NASDAQ BCPC traded up $0.76 during midday trading on Friday, reaching $139.26. 58,508 shares of the stock traded hands, compared to its average volume of 103,753. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.12 and a quick ratio of 1.38. The stock has a market capitalization of $4.49 billion, a PE ratio of 41.34, a P/E/G ratio of 4.25 and a beta of 0.71. Balchem has a one year low of $110.74 and a one year high of $159.52. The company's 50 day moving average is $152.25 and its 200 day moving average is $139.84.
Hedge Funds Weigh In On Balchem
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its stake in Balchem by 123.0% in the fourth quarter. Signaturefd LLC now owns 165 shares of the basic materials company's stock valued at $25,000 after purchasing an additional 91 shares during the last quarter. Principal Securities Inc. acquired a new stake in Balchem in the fourth quarter worth about $28,000. Operose Advisors LLC acquired a new stake in Balchem in the third quarter worth about $31,000. GAMMA Investing LLC acquired a new stake in Balchem in the fourth quarter worth about $56,000. Finally, YHB Investment Advisors Inc. acquired a new stake in Balchem in the first quarter worth about $69,000. Hedge funds and other institutional investors own 87.91% of the company's stock.
Insiders Place Their Bets
In other Balchem news, CAO William A. Backus sold 7,000 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $155.19, for a total value of $1,086,330.00. Following the sale, the chief accounting officer now owns 5,914 shares in the company, valued at $917,793.66. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, SVP Michael Robert Sestrick sold 11,100 shares of the firm's stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $153.21, for a total transaction of $1,700,631.00. Following the transaction, the senior vice president now owns 6,736 shares in the company, valued at $1,032,022.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO William A. Backus sold 7,000 shares of the firm's stock in a transaction on Monday, February 26th. The shares were sold at an average price of $155.19, for a total value of $1,086,330.00. Following the transaction, the chief accounting officer now owns 5,914 shares in the company, valued at approximately $917,793.66. The disclosure for this sale can be found here. Insiders have sold a total of 76,630 shares of company stock worth $11,843,249 over the last quarter. Company insiders own 1.77% of the company's stock.
Balchem Company Profile
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Read More
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
